s, and attract and retain employees; the Company's ability to complete additional acquisitions, and to integrate newly acquired businesses "including the recent acquisition of Liquent, Inc.", or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.
Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2012 as filed with the SEC on February 4, 2013, which "Risk Factors" discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL International CorporationConsolidated Condensed Statement of Operations(Unaudited)Three Months EndedNine Months Ended(in thousands, except per share data)March 31, 2013March 31, 2012March 31, 2013March 31, 2012Service revenue$ 454,493$ 355,992$ 1,271,314$ 1,003,897Reimbursement revenue68,95856,037197,794156,592Total revenue523,451412,0291,469,1081,160,489Costs and expenses:Direct costs311,917241,445892,646691,718Reimbursable out-of-pocket expenses68,95856,037197,794156,592Selling, general and administrative 88,03867,159229,975192,506Depreciation15,77315,16646,03044,199Amortization2,8912,1986,0186,542Restructuring (benefit) charge(732)1,807(1,150)5,669Total costs and expense
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 Related biology technology :1
|SOURCE PAREXEL International Corporation|
Copyright©2012 PR Newswire.
All rights reserved
. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes2
. PAREXEL International to Present at J.P. Morgan Healthcare Conference3
. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts4
. PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs5
. PAREXEL Chairman and CEO to Deliver Keynote at MassBio CRO/CMO Symposium6
. PAREXEL International To Present At Goldman Sachs Healthcare Conference And Jefferies Healthcare Conference7
. PAREXEL International Reports First Quarter Fiscal Year 2013 Results8
. PAREXEL International to Present at Morningstar Conference9
. PAREXEL Announces Date of Third Quarter Fiscal Year 2013 Earnings Release and Conference Call10
. UV Flu Technologies Expands Its International Footprint11
. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign